Vanguard Capital Management filed a Schedule 13G with the SEC on October 30, 2026, disclosing beneficial ownership of 1,970,108 shares of Alto Neuroscience Inc common stock as of September 30, 2026.

Key Highlights

  • Aggregate beneficial ownership: Vanguard Capital Management reported holding 1,970,108 shares of Alto Neuroscience Inc common stock.
  • Percent of class: The reported stake represents 5.02% of the outstanding class of common stock.
  • Sole dispositive power: Vanguard Capital Management holds sole power to dispose of all 1,970,108 shares.
  • Sole voting power: Sole voting power is reported over 279,355 shares; shared voting power is reported as 0.
  • Event date: The event triggering the filing occurred on September 30, 2026.
  • Filing entity type: Vanguard Capital Management is identified as an investment adviser (type: IA), organized in Pennsylvania.

Vanguard Capital Management's Disclosed Position in Alto Neuroscience

According to the Schedule 13G filing, Vanguard Capital Management, headquartered at 100 Vanguard Blvd, Malvern, PA 19355, reported aggregate beneficial ownership of 1,970,108 shares of common stock of Alto Neuroscience Inc (CUSIP 02157Q109). The filing states that the ownership represents 5.02% of the class. Alto Neuroscience Inc is headquartered at 369 S San Antonio Rd, Los Altos, CA 94022.

The filing discloses that Vanguard Capital Management holds sole power to vote or direct the vote of 279,355 shares, and sole power to dispose of or direct the disposition of the full 1,970,108 shares. Shared voting power and shared dispositive power are each reported as 0. The filing notes, in accordance with SEC Release No. 34-39538 (January 12, 1998), that the Schedule 13G reflects securities beneficially owned or deemed to be beneficially owned by Vanguard Capital Management LLC and certain affiliates and business divisions, including Vanguard Asset Management Limited, Vanguard Fiduciary Trust Company, Vanguard Global Advisers, LLC, and Vanguard Investments Australia Ltd.

The filing further discloses that the reported securities include shares held by Vanguard funds or sleeves thereof over which Vanguard Capital Management LLC exercises dispositive power, as well as securities held by clients over which the named affiliates exercise dispositive and/or voting power. According to the filing, Vanguard Capital Management, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, has the right to receive or direct the receipt of dividends from, or proceeds from the sale of, the reported securities. The filing states that no single other person's interest in the reported securities exceeds 5%. The statement was signed by My Trieu-Gatt, Authorized Signatory, Head of Global Fund Administration, on October 30, 2026.

What Was Disclosed

Vanguard Capital Management filed a Schedule 13G reporting beneficial ownership of 1,970,108 shares, or 5.02%, of Alto Neuroscience Inc common stock as of September 30, 2026, with sole dispositive power over all reported shares and sole voting power over 279,355 shares.